Skip to content
OpenCapital
Get started

Indivior Pharmaceuticals, Inc. INDV SG&A

SG&A at other companies

Alkermes logo
AlkermesALKS
$264.59M+54.1%
JAN
Janus Living JAN
$6.32M+63.1%

Segments

By segment

See full
Reportable Segment$124M-6.8%

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.53B+213%

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's SG&A?
Indivior Pharmaceuticals, Inc. (INDV) reported SG&A of $124M in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's SG&A changed year-over-year?
Indivior Pharmaceuticals, Inc. 's SG&A decreased by 6.8% year-over-year, from $133M to $124M.
What is the long-term trend for Indivior Pharmaceuticals, Inc. 's SG&A?
Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc. 's SG&A has grown at a 10.9% compound annual growth rate (CAGR), from $466M to $635M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.